Hyam I. Levitsky, MD, Joins Antigenics' Board of Directors

"Hy's research has formed the basis for the development of severalnovel immunotherapeutic agents for a variety of different cancers,"said Garo H. Armen, PhD, chairman and CEO of Antigenics. "His additionbrings a substantial level of relevant scientific and clinicalexpertise. We are delighted to have him on board as we focus on ourfour priority clinical-stage programs in the field of vaccines andcancer therapeutics."

Dr. Levitsky's laboratory research involves basic studies ofantigen processing and presentation, T-cell co-stimulation, T-cellpriming versus tolerance, and the evolution of tumor-specific immunityduring immune reconstitution. He has received numerous awards for hisresearch, including the Stohlman Scholars Award from the Leukemia andLymphoma Foundation of America, The Senior Research Award from theMultiple Myeloma Research Foundation, Research Awards from the CapCUREfoundation, The American Cancer Society and the National Institutes ofHealth. In 2001, he was elected to the American Society for ClinicalInvestigation.

Dr. Levitsky received his undergraduate degree in engineering fromthe University of Pennsylvania in 1980, and his medical degree fromthe Johns Hopkins University School of Medicine in 1984. He did hisinternship and residency in internal medicine at Johns HopkinsHospital, and his fellowship at the Johns Hopkins Oncology Center.

About Antigenics

Antigenics (NASDAQ: AGEN) is working to develop treatments forcancers, infectious diseases and autoimmune disorders. The company'sinvestigational product portfolio includes Oncophage(R) (vitespen), apatient-specific therapeutic cancer vaccine being evaluated in severalindications; Aroplatin(TM), a liposomal, third-generation platinumchemotherapeutic; ATRA-IV, a liposomal retinoic acid; AG-707, atherapeutic vaccine for the treatment of genital herpes; AU-801, apreclinical program targeting autoimmune disorders; and QS-21, anadjuvant being evaluated by Antigenics' corporate partners in severallate-stage clinical trials. For more information, please visitwww.antigenics.com.

Participation of Dr. Levitsky on Antigenics' board of directorsdoes not constitute or imply endorsement by the Johns HopkinsUniversity or the Johns Hopkins University Hospital and Health System.